Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Merck & Co., Inc. — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.53, while Merck & Co., Inc. trades at $126.1 (market cap $318.26B). The key difference: Merck & Co., Inc. pays a 2.64% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $129.52 |
52-Week Low | $43.28 | $77.60 |
Market Cap | — | $318.26B |
Enterprise Value | — | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
Merck (MRK) trades at $125.99, down 0.62% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue grew to $65.01B in 2025, and net income reached $18.25B. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, driven by earnings momentum, strategic acquisitions, and strong institutional interest. Risks include rising debt levels and competitive pressures in the pharma sector. With a consensus price target of $139.33, representing ~11% upside, the stock offers growth potential but requires monitoring of execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
